Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2174/1574887116666210824093611 http://scihub22266oqcxt.onion/10.2174/1574887116666210824093611 34429051!ä!34429051 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Rev+Recent+Clin+Trials 2021 ; 16 (4): 381-389 Nephropedia Template TP {{tp|p=34429051|t=2021. Systematic Review on Treatment Trials of Tocilizumab: A Repurposing Drug against COVID-19 |pdf=|usr=}}{{34429051}} gab.com Text Systematic Review on Treatment Trials of Tocilizumab: A Repurposing Drug against COVID-19 JO: Rev Recent Clin Trials http://www.kidney.de/pget.php?&tw=1&pmid=34429051 #FOAvip BACKGROUND: Coronavirus disease (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become a global issue today. There exists an ongoing health crisis all over the world, and efficacious drugs against COVID-19 are not available yet. Therefore, on an urgent basis, scientists are looking for safe and efficacious drugs against SARSCoV- 2. METHODS: The reported individual patient data and clinical outcomes, including the rate of recovery and mortality, patients' characteristics, and complications, are reviewed. Randomized controlled trials, single-center cohort studies, and different case studies are provided, and the PICO model is used to illustrate the outcomes. RESULTS: There exist several FDA (U.S Food and Drug Administration) approved anti coronavirus drugs that sometimes are unsuccessful in curing COVID-19 critical conditions. It has been observed that a humanized monoclonal antibody, Tocilizumab (licensed for the treatment of rheumatoid arthritis), targeting the interleukin-6 (IL-6) receptor, has an integral role in the treatment of COVID-19. CONCLUSION: The cause behind the mortality of COVID-19 patients was found to be the Cytokine Release Syndrome (CRS). Therefore, besides other antiviral drugs, the utilization of tocilizumab should also be considered as it can effectively block IL-6 and reduce the inflammatory signal. Twit Text FOAVip Systematic Review on Treatment Trials of Tocilizumab: A Repurposing Drug against COVID-19 ????Rev Recent Clin Trials http://www.kidney.de/pget.php?&tw=1&pmid=34429051 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34429051 #FOAvip English Wikipedia <ref>{{Cite pmid|34429051}}</ref> Systematic Review on Treatment Trials of Tocilizumab: A Repurposing Drug against COVID-19 #MMPMID34429051 Banerjee S; Mahapatra AK Rev Recent Clin Trials 2021[]; 16 (4): 381-389 PMID34429051show ga BACKGROUND: Coronavirus disease (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become a global issue today. There exists an ongoing health crisis all over the world, and efficacious drugs against COVID-19 are not available yet. Therefore, on an urgent basis, scientists are looking for safe and efficacious drugs against SARSCoV- 2. METHODS: The reported individual patient data and clinical outcomes, including the rate of recovery and mortality, patients' characteristics, and complications, are reviewed. Randomized controlled trials, single-center cohort studies, and different case studies are provided, and the PICO model is used to illustrate the outcomes. RESULTS: There exist several FDA (U.S Food and Drug Administration) approved anti coronavirus drugs that sometimes are unsuccessful in curing COVID-19 critical conditions. It has been observed that a humanized monoclonal antibody, Tocilizumab (licensed for the treatment of rheumatoid arthritis), targeting the interleukin-6 (IL-6) receptor, has an integral role in the treatment of COVID-19. CONCLUSION: The cause behind the mortality of COVID-19 patients was found to be the Cytokine Release Syndrome (CRS). Therefore, besides other antiviral drugs, the utilization of tocilizumab should also be considered as it can effectively block IL-6 and reduce the inflammatory signal. |*COVID-19 Drug Treatment[MESH] |*Pharmaceutical Preparations[MESH] |Antibodies, Monoclonal, Humanized[MESH] |Drug Repositioning[MESH] |Humans[MESH] |SARS-CoV-2[MESH]Systematic Review on Treatment Trials of Tocilizumab: A Repurposing Dr(epmc).pdf DeepDyve Pubget Overpricing